Target Name: CD276
NCBI ID: G80381
Review Report on CD276 Target / Biomarker Content of Review Report on CD276 Target / Biomarker
CD276
Other Name(s): CD276 antigen | CD276 antigen (isoform b) | CD276 variant 1 | B7H3 | CD276_HUMAN | 4Ig-B7-H3 | CD276 molecule, transcript variant 2 | CD276 molecule, transcript variant 1 | Costimulatory molecule | B7 homolog 3 | CD276 molecule | CD276 variant 2 | B7RP-2 | costimulatory molecule | CD276 antigen (isoform a) | B7-H3

CD276 Antigen as a Potential Drug Target and Biomarker

CD276 is a cell surface antigen that is expressed in various tissues, including the gastrointestinal tract, skin, heart, and brain. It is a member of the immunoglobulin superfamily and has been implicated in several biological processes, including cell signaling, inflammation, and immune surveillance. The identification of CD276 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases.

CD276 Antigen as a Drug Target

CD276 has been identified as a potential drug target due to its unique structure and expression pattern. The CD276 antigen is expressed in most tissues and cells, making it an attractive target for small molecules or antibodies that can modulate its expression levels. Additionally, its high expression level in the immune cells, such as T cells and macrophages, makes it an attractive target for drugs that aim to enhance the immune response against tumors.

CD276 has been shown to play a role in several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. For example, studies have shown that CD276 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. Therefore, targeting CD276 has been shown to be an effective way to enhance the treatment of these cancers.

In addition to its potential as a cancer therapeutic, CD276 has also been shown to be a potential target for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by chronic inflammation and the immune system's overreaction, which can be attributed to the chronic activation of the immune system and the production of autoantibodies. By targeting CD276, researchers have been able to develop new treatments that can suppress the immune system's overreaction and alleviate the symptoms of these diseases.

CD276 as a Biomarker

In addition to its potential as a drug target, CD276 has also been shown to be a potential biomarker for several diseases. The expression of CD276 is known to be associated with several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. Therefore, the levels of CD276 expression can be used as a diagnostic or monitoring tool for these diseases.

One of the most promising applications of CD276 as a biomarker is its potential to serve as a marker for cancer. The expression of CD276 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. Therefore, researchers have been able to use CD276 as a diagnostic tool for cancer and to identify new potential targets for cancer therapies.

In addition to its use as a cancer biomarker, CD276 has also been shown to be a potential biomarker for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by chronic inflammation and the immune system's overreaction, which can be attributed to the chronic activation of the immune system and the production of autoantibodies. Therefore, CD276 has been shown to be an effective biomarker for these diseases, as its levels can be used to monitor the effectiveness of new treatments.

Conclusion

CD276 is a cell surface antigen that has been shown to play a role in several biological processes, including cell signaling, inflammation, and immune surveillance. Its unique structure and expression pattern make it an attractive target for small molecules or antibodies that can modulate its expression levels. Additionally, its high expression level in the immune cells makes it an attractive target for drugs that aim to enhance the immune response against tumors.

Furthermore, CD276 has been shown to be a potential drug target and biomarker for several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. Its expression is known to be associated with

Protein Name: CD276 Molecule

Functions: May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling

The "CD276 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD276 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45